Imprida HCT

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
29-10-2012
Summary of Product characteristics Summary of Product characteristics (SPC)
29-10-2012
Public Assessment Report Public Assessment Report (PAR)
29-10-2012

Active ingredient:

Амлодипин, валсартан, hydrochlorothiazide

Available from:

Novartis Europharm Ltd.

ATC code:

C09DX01

INN (International Name):

amlodipine, valsartan, hydrochlorothiazide

Therapeutic group:

Антагонисти на ангиотензин II, равнина, антагонисти на ангиотензин II в комбинация

Therapeutic area:

Хипертония

Therapeutic indications:

Лечение на есенциална хипертония като субституиращата терапия при възрастни пациенти, чието кръвно налягане е адекватно контролирано на комбинацията амлодипин, валсартан и хидрохлоротиазид (HCT), взети като три Еднокомпонентна формули или като Dual-компонент и Еднокомпонентна формулировка.

Product summary:

Revision: 3

Authorization status:

Отменено

Authorization date:

2009-10-15

Patient Information leaflet

                                161
Б. ЛИСТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
162
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
IMPRIDA HCT 5 MG/160 MG/12,5 MG ФИЛМИРАНИ ТАБЛЕТКИ
Амлодипин/валсартан/хидрохлоротиазид
(Amlodipine/valsartan/hydrochlorothiazide)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може да
им навреди, независимо от това, че
техните симптоми са същите като
Вашите.
-
Ако някоя от нежеланите лекарствени
реакции стане сериозна или забележите
други,
неописани в тази листовка нежелани
реакции, моля уведомете Вашия лекар
или фармацевт.
В ТАЗИ ЛИСТОВКА:
1.
Какво представлява Imprida HCT и за какво
се използва
2.
Преди да приемете Imprida HCT
3.
Как да приемате Imprida HCT
4.
Възможни нежелани реакции
5.
Как да съхранявате Imprida HCT
6.
Допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА IMPRIDA HCT И ЗА КАКВО
СЕ ИЗПОЛЗВА
Imprida HCT таблетки съдържат три вещества
наречени амлодипин, валсартан и
хидрохлоротиазид.
И трите ве
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Imprida HCT 5 mg/160 mg/12,5 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка филмирана таблетка съдържа 5 mg
амлодипин _(amlodipine)_ (като амлодипин
безилат), 160 mg
валсартан _(valsartan)_ и 12,5 mg
хидрохлоротиазид _(hydrochlorothiazide)._
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка (таблетка)
Бели, овални, двойно изпъкнали
таблетки със скосени ръбове, с
вдлъбнато релефно означение
“NVR” от едната страна и “VCL” от
другата.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Лечение на есенциална хипертония като
заместителна терапия при възрастни
пациенти, при които е
постигнат задоволителен контрол
върху артериалното налягане с
комбинацията амлодипин,
валсартан и хидрохлоротиазид (HCT),
прилагани като три отделни
лекарствени форми или като
фиксирана двойна комбинация и отделна
лекарствена форма.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Препоръчваната доза Imprida HCT е една
таблетка дневно, за предпочитане
сутрин.
Преди да преминат на лечение с Imprida HCT
пацие
                                
                                Read the complete document

Similar products

Active ingredient Амлодипин, валсартан, hydrochlorothiazide

Амлодипин, валсартан, hydrochlorothiazide

ATC code C09DX01

C09DX01

Marketed by Novartis Europharm Ltd.

Novartis Europharm Ltd.

INN (International Name) amlodipine, valsartan, hydrochlorothiazide

amlodipine, valsartan, hydrochlorothiazide

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 29-10-2012
Summary of Product characteristics Summary of Product characteristics Spanish 29-10-2012
Public Assessment Report Public Assessment Report Spanish 29-10-2012
Patient Information leaflet Patient Information leaflet Czech 29-10-2012
Summary of Product characteristics Summary of Product characteristics Czech 29-10-2012
Public Assessment Report Public Assessment Report Czech 29-10-2012
Patient Information leaflet Patient Information leaflet Danish 29-10-2012
Summary of Product characteristics Summary of Product characteristics Danish 29-10-2012
Public Assessment Report Public Assessment Report Danish 29-10-2012
Patient Information leaflet Patient Information leaflet German 29-10-2012
Summary of Product characteristics Summary of Product characteristics German 29-10-2012
Public Assessment Report Public Assessment Report German 29-10-2012
Patient Information leaflet Patient Information leaflet Estonian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Estonian 29-10-2012
Public Assessment Report Public Assessment Report Estonian 29-10-2012
Patient Information leaflet Patient Information leaflet Greek 29-10-2012
Summary of Product characteristics Summary of Product characteristics Greek 29-10-2012
Public Assessment Report Public Assessment Report Greek 29-10-2012
Patient Information leaflet Patient Information leaflet English 29-10-2012
Summary of Product characteristics Summary of Product characteristics English 29-10-2012
Public Assessment Report Public Assessment Report English 29-10-2012
Patient Information leaflet Patient Information leaflet French 29-10-2012
Summary of Product characteristics Summary of Product characteristics French 29-10-2012
Public Assessment Report Public Assessment Report French 29-10-2012
Patient Information leaflet Patient Information leaflet Italian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Italian 29-10-2012
Public Assessment Report Public Assessment Report Italian 29-10-2012
Patient Information leaflet Patient Information leaflet Latvian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Latvian 29-10-2012
Public Assessment Report Public Assessment Report Latvian 29-10-2012
Patient Information leaflet Patient Information leaflet Lithuanian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-10-2012
Public Assessment Report Public Assessment Report Lithuanian 29-10-2012
Patient Information leaflet Patient Information leaflet Hungarian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Hungarian 29-10-2012
Public Assessment Report Public Assessment Report Hungarian 29-10-2012
Patient Information leaflet Patient Information leaflet Maltese 29-10-2012
Summary of Product characteristics Summary of Product characteristics Maltese 29-10-2012
Public Assessment Report Public Assessment Report Maltese 29-10-2012
Patient Information leaflet Patient Information leaflet Dutch 29-10-2012
Summary of Product characteristics Summary of Product characteristics Dutch 29-10-2012
Public Assessment Report Public Assessment Report Dutch 29-10-2012
Patient Information leaflet Patient Information leaflet Polish 29-10-2012
Summary of Product characteristics Summary of Product characteristics Polish 29-10-2012
Public Assessment Report Public Assessment Report Polish 29-10-2012
Patient Information leaflet Patient Information leaflet Portuguese 29-10-2012
Summary of Product characteristics Summary of Product characteristics Portuguese 29-10-2012
Public Assessment Report Public Assessment Report Portuguese 29-10-2012
Patient Information leaflet Patient Information leaflet Romanian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Romanian 29-10-2012
Public Assessment Report Public Assessment Report Romanian 29-10-2012
Patient Information leaflet Patient Information leaflet Slovak 29-10-2012
Summary of Product characteristics Summary of Product characteristics Slovak 29-10-2012
Public Assessment Report Public Assessment Report Slovak 29-10-2012
Patient Information leaflet Patient Information leaflet Slovenian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Slovenian 29-10-2012
Public Assessment Report Public Assessment Report Slovenian 29-10-2012
Patient Information leaflet Patient Information leaflet Finnish 29-10-2012
Summary of Product characteristics Summary of Product characteristics Finnish 29-10-2012
Public Assessment Report Public Assessment Report Finnish 29-10-2012
Patient Information leaflet Patient Information leaflet Swedish 29-10-2012
Summary of Product characteristics Summary of Product characteristics Swedish 29-10-2012
Public Assessment Report Public Assessment Report Swedish 29-10-2012
Patient Information leaflet Patient Information leaflet Norwegian 29-10-2012
Summary of Product characteristics Summary of Product characteristics Norwegian 29-10-2012
Patient Information leaflet Patient Information leaflet Icelandic 29-10-2012
Summary of Product characteristics Summary of Product characteristics Icelandic 29-10-2012

Search alerts related to this product

Alerts Imprida HCT Амлодипин, валсартан, hydrochlorothiazide amlodipine, valsartan,

Imprida HCT Амлодипин, валсартан, hydrochlorothiazide amlodipine, valsartan,

View documents history

Documents history Documents history

Imprida HCT